NASDAQ:CLSN - Celsion Stock Price, Forecast & News

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Celsion Co. (NASDAQ:CLSN) released its quarterly earnings results on Friday, November, 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 57.46% and a negative net margin of 1,653.20%. View Celsion's Earnings History.

Celsion is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Celsion.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.

News headlines about CLSN stock have trended very negative on Saturday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near term. View News Stories for Celsion.

Some companies that are related to Celsion include AcelRx Pharmaceuticals (ACRX), Cassava Sciences (SAVA), TapImmune (MRKR), Savara (SVRA), Helix Biopharma (HBPCF), Sierra Oncology (SRRA), Newron Pharmaceuticals (NWPHF), REDHILL BIOPHAR/S (RDHL), CymaBay Therapeutics (CBAY), Zynerba Pharmaceuticals (ZYNE), Galmed Pharmaceuticals (GLMD), ProMetic Life Sciences (PFSCF), vTv Therapeutics (VTVT), Northwest Biotherapeutics (NWBO) and Gemphire Therapeutics (GEMP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Rexahn Pharmaceuticals (REXN), Amarin (AMRN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), BIOLINERX LTD/S (BLRX), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC) and Catalyst Pharmaceuticals (CPRX).

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.52.

Celsion has a market capitalization of $34.59 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.View Additional Information About Celsion.

The official website for Celsion is http://www.celsion.com/.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]